Phase 3 N=306 Addiction Treatment in Russia: Oral vs. Naltrexone Implant
Heroin Dependence · Opioid-Related Disorders
Primary: Retention Without Relapse to Heroin Addiction (Measured at Month 6) — 54; 16; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=164 A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines
Human Rabies
Primary: Percentage of Participants With Serum Rabies Virus Neutralizing Activity — 94.3; 97.1; 97.1; 100 percentage of participants — p=0.4187
Phase 1 N=21 A Study of IMC-A12 in Advanced Solid Tumors
Tumors
Primary: Summary Listing of Percentage of Participants Reporting Treatment-Emergent Adverse Events — 100; 85.7; 100; 85.7 percentage of participants
Phase 3 N=15 Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 86.7 percentage of participants
Phase 2 N=20 A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Metastatic Renal Cell Carcinoma
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicity (DLT) — 1; 0; 0; 0 Participants
N/A N=33 Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye
Glaucoma
Primary: Lamina Cribrosa (Boundaries of the Retinal Layers) Measurements — 264.3; 273.3; 276.2 micro-ohms
N/A N=322 Post-Approval Clinical Trial Comparing the Long Term Safety and Effectiveness Coflex vs. Fusion to Treat Lumbar Spinal Stenosis
Spinal Stenosis
Primary: Number of Subjects With Improvement of at Least 15 Points in ODI — 41; 101 Participants
N/A N=701 Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
End Stage Renal Disease (ESRD)
Primary: Positive Blood Cultures (PBC's) Per 1,000 Central Venous Catheter (CVC)-Days — 0.28; 0.75 PBCs per 1,000 CVC-days
N/A N=69 Routine Use of Sensor-Augmented Pump Therapy - a Follow up Study
Diabetes
Primary: Daily Usage of Blood Glucose Test (BG Testing) — 4.35 number of blood glucose test per day
Phase 4 N=37 Antiplatelet Therapy After Cardiac Arrest
Cardiac Arrest · Postresuscitation Syndrome · Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)
Primary: VerifyNow P2Y12Test - Platelet Reactivity — 238; 101 PRU
N/A N=200 Antimullerian Hormone Versus Antral Follicle Count for Determination of Gonadotrophin Dosing in IVF
Infertility
Primary: Percentage of Subjects Having Desired Ovarian Response — 49; 54 Participants — p=0.479
Phase 3 N=58 Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.
Postoperative Pain
Primary: Summary of Visual Analog Scales (VAS) of Pain Intensity Change From Baseline by Treatment Group With Single Dose of Oxymorphone IR Tablet and Multiple Dose of…
Phase 3 N=296 Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing Colonoscopy
Bowel Cleansing
Primary: Adjusted Percentage of Patients With Successful Overall Colon Preparation, Assessed by the Global Score of the Boston Bowel Preparation Scale (BBPS). — 97.18; 97.65…
N/A N=22 Immune Profile in Subjects With New Onset Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B…
Phase 2 N=102 Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
Leukemia
Primary: Response Rate — 55.2 percentage